RxDoctor Payments Data

Jordan Daniels, PA

Physician Assistant · Henderson, NVNPI 1093441891

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,336 of the $11,742 with a category attached, or 71.0%. 19 manufacturers reported payments, led by Pfizer at 29.0% of the total. 2025 is the largest year on record at $6,198, more than ten times the $547 reported in 2022. Among physician assistant clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,742in general payments, 2019–2025

Across 449 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Johnson & Johnson$900
  • Galderma Laboratories, L.p.$731
  • Sun Pharmaceutical Industries Inc.$685
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$2,32520%
  • Speaking & faculty fees$5345%
  • Food & beverage$8,33671%
  • Education$5475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,742 in reported general payments places this provider in the 95th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$187,610
Medicare patients
458
Services billed
3,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$85,353
RinvoqUpadacitinib12$78,534
Clobetasol Propionate63$2,110
Metronidazole25$1,700
Doxycycline Hyclate13$1,390
Fluorouracil18$1,307
Betamethasone Valerate49$1,241
Mupirocin152$1,131
Ketoconazole76$1,045
Cephalexin160$967
Triamcinolone Acetonide56$878
Tretinoin13$694
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$534
Clindamycin Phosphate13$343
Hydrocortisone34$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,534$78,53412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →